Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
Department of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden.
ACS Appl Mater Interfaces. 2021 May 26;13(20):23410-23422. doi: 10.1021/acsami.1c02834. Epub 2021 May 12.
Nanomedicine is seen as a potential central player in the delivery of personalized medicine. Biocompatibility issues of nanoparticles have largely been resolved over the past decade. Despite their tremendous progress, less than 1% of applied nanosystems can hit their intended target location, such as a solid tumor, and this remains an obstacle to their full ability and potential with a high translational value. Therefore, achieving immune-tolerable, blood-compatible, and biofriendly nanoparticles remains an unmet need. The translational success of nanoformulations from bench to bedside involves a thorough assessment of their design, compatibility beyond cytotoxicity such as immune toxicity, blood compatibility, and immune-mediated destruction/rejection/clearance profile. Here, we report a one-pot process-engineered synthesis of ultrasmall gold nanoparticles (uGNPs) suitable for better body and renal clearance delivery of their payloads. We have obtained uGNP sizes of as low as 3 nm and have engineered the synthesis to allow them to be accurately sized (almost nanometer by nanometer). The synthesized uGNPs are biocompatible and can easily be functionalized to carry drugs, peptides, antibodies, and other therapeutic molecules. We have performed cell viability assays, immunotoxicity assays, inflammatory cytokine analysis, a complement activation study, and blood coagulation studies with the uGNPs to confirm their safety. These can help to set up a long-term safety-benefit framework of experimentation to reveal whether any designed nanoparticles are immune-tolerable and can be used as payload carriers for next-generation vaccines, chemotherapeutic drugs, and theranostic agents with better body clearance ability and deep tissue penetration.
纳米医学被视为个性化医疗的潜在核心手段。在过去十年中,纳米颗粒的生物相容性问题已基本得到解决。尽管它们取得了巨大的进展,但只有不到 1%的应用纳米系统能够到达其预定的目标位置,例如实体瘤,这仍然是它们充分发挥能力和潜力的障碍,具有很高的转化价值。因此,实现免疫耐受、血液相容和生物友好的纳米颗粒仍然是一个未满足的需求。纳米制剂从实验室到临床的转化成功涉及对其设计的全面评估,除细胞毒性外,还包括免疫毒性、血液相容性和免疫介导的破坏/排斥/清除特性等兼容性。在这里,我们报告了一种适用于更好的体内和肾脏清除其有效载荷的超小金纳米颗粒(uGNPs)的一锅法过程工程合成方法。我们已经获得了低至 3nm 的 uGNP 尺寸,并对合成进行了工程设计,使其能够精确地进行尺寸控制(几乎纳米级)。合成的 uGNPs 具有生物相容性,并且可以很容易地进行功能化以携带药物、肽、抗体和其他治疗分子。我们已经使用 uGNPs 进行了细胞活力测定、免疫毒性测定、炎症细胞因子分析、补体激活研究和血液凝固研究,以确认其安全性。这些研究可以帮助建立一个长期的安全效益实验框架,以揭示任何设计的纳米颗粒是否具有免疫耐受能力,并可作为下一代疫苗、化疗药物和治疗诊断剂的有效载荷载体,具有更好的体内清除能力和深层组织穿透能力。